Navigation Links
Pacira Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering

PARSIPPANY, N.J., Feb. 3, 2011 /PRNewswire/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced the pricing of its initial public offering of 6,000,000 shares of its common stock at $7.00 per share, before underwriting discounts and commissions. All of the common stock is being offered by Pacira. The shares are expected to begin trading on the NASDAQ Global Market under the symbol "PCRX" on February 3, 2011. In addition, Pacira has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares to cover over-allotments, if any.

Barclays Capital Inc. and Piper Jaffray & Co. are acting as joint book-running managers for the offering. Wedbush PacGrow Life Sciences and Brean Murray, Carret & Co. are acting as co-managers for the offering.

The offering of these securities will be made only by means of a prospectus, copies of which may be obtained from Barclays Capital Inc., c/o Broadridge Financial Solutions, at 1155 Long Island Avenue, Edgewood, NY 11717, or by calling 1-888-603-5847 or by emailing; or from Piper Jaffray & Co. at 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402, by calling 1-800-747-3924.

A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission.

About PaciraPacira Pharmaceuticals, Inc. is an emerging specialty pharmaceutical company focused on the development, commercialization and manufacture of novel pharmaceutical products, based on its proprietary DepoFoam® drug delivery technology, for use in hospitals and ambulatory surgery centers. The company's most advanced product candidate, EXPAREL™, a bupivacaine-based product, has completed Phase 3 clinical development for postoperative analgesia by infiltration.  EXPAREL consists of bupivacaine encapsulated in DepoFoam, which is designed to address the limitations of widely used medications by enhancing their dosing and/or administration profile. Additional information about Pacira is available at

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Contacts:James Scibetta, Chief Financial Officer, Pacira Pharmaceuticals, Inc.(973) 254-3570Jennifer Beugelmans, Pure Communications, Inc.(646) 596-7473

SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
2. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)
3. Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment
4. Pacira Pharmaceuticals Announces FDA Acceptance of EXPAREL™ New Drug Application for Pain Management
5. Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Societys 57th Annual Meeting
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
10. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
11. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
Post Your Comments:
(Date:11/25/2015)... , November 25, 2015 ... Investors"), pursuant to which BioLight and the New Investors ... Ltd. subsidiary ("IOPtima") via a private placement. The financing ... its innovative IOPtimate™ system used in the treatment of ... pathway process for the IOPtimate™ system with the U.S. ...
(Date:11/25/2015)... 2015 Developmental, commercial, and regulatory/legal ... profitability of pharmaceutical products, says GBI Research ... regulatory/legal strategies all play a key role in boosting ... . --> Developmental, commercial, ... in boosting the profitability of pharmaceutical products, says ...
(Date:11/25/2015)... Research and Markets ( ) has ... Global Forecast to 2020" report to their offering. ... 37.21% of the total market share in 2014. The ... is projected to growth at the highest CAGR between ... to the fast growing water, industrial gas treatment, pharmaceutical, ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... Bcureful—a non-profit organization devoted to ... raising public awareness of the disorder while helping to bring expert medical care ... to bolster progress at the Tuberous Sclerosis Complex Center at Ann & Robert ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... to offer their patients the many benefits of the revolutionary BIOLASE WaterLase iPlus ... cutting and scraping tools traditionally used by a dentist in Gettysburg, PA ...
(Date:11/24/2015)... ... 24, 2015 , ... ThirdLove, the fast-growing bra company that ... offering 40% off select bras and underwear styles, now through Saturday, November 28th. ... technology and the latest fashion, quickly becoming the next generation of luxury bras. ...
(Date:11/24/2015)... ... 24, 2015 , ... Preparing for the LDT Regulation:, CLIA Won’t Satisfy the ... , FDA has long asserted that design and manufacture of Laboratory Developed Tests ... do not meet the device regulations. , Come up short in an inspection and ...
(Date:11/24/2015)... ... November 24, 2015 , ... United Benefit Advisors (UBA), ... & Company as its newest Partner Firm. Based in Jefferson City, Missouri, their ... trusted advisor regardless of whether that client is a business, a family, or ...
Breaking Medicine News(10 mins):